Mainz Biomed (QUCY) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
4 Jun, 2026Company overview and business model
Focuses on developing intelligent, scalable platforms integrating AI and quantum computing for next-generation control systems in unmanned, aerial, and underwater vehicles, including drones and robotic fleets.
Aims to address limitations of classical computing in autonomous vehicle control by enabling real-time, high-dimensional, multi-objective optimization.
Targets applications in defense, commercial logistics, disaster response, and critical infrastructure operations.
Operates as a Dutch public company with a U.S. subsidiary, Quantum Drones Corporation, and principal offices in West Palm Beach, Florida.
Recently changed its name from Mainz Biomed N.V. to Quantum Cyber N.V. in April 2026.
Financial performance and metrics
As of June 2, 2026, the public float was $78,524,586, based on 22,767,254 ordinary shares outstanding and a last reported sale price of $3.56 per share on May 21, 2026.
Ordinary shares are listed on Nasdaq Capital Market under the symbol “QUCY.”
Use of proceeds and capital allocation
Net proceeds from securities sales are intended for general corporate purposes, including working capital and capital expenditures.
More detailed allocation and milestones will be provided in applicable prospectus supplements.
Latest events from Mainz Biomed
- Annual meeting to vote on key proposals, board changes, and expansion into quantum cybersecurity.QUCY
Proxy filing1 Jun 2026 - Annual meeting to vote on key proposals, board changes, and expanded authorizations.QUCY
Proxy filing22 May 2026 - Strategic pivot, asset sales, and capital raises mark Q1 2026 amid ongoing losses and cash improvement.QUCY
Q1 202615 May 2026 - 2025 saw a strategic pivot to pancreatic cancer diagnostics, a 40% revenue drop, and a $16.2M net loss.QUCY
H2 202531 Mar 2026 - Approval of all proposals enables a $6M investment, board overhaul, and recapitalization.QUCY
Proxy filing25 Mar 2026 - Shareholders will vote on a $6M investment, board overhaul, and major capital structure changes.QUCY
Proxy Filing12 Mar 2026 - Offering up to $150M in securities to advance innovative cancer diagnostics amid high risk.QUCY
Registration Filing16 Dec 2025 - Up to 4.59 million shares and units are offered, with Maxim Group LLC as placement agent.QUCY
Registration Filing30 Nov 2025 - IPO aims to fund CRC diagnostics growth amid financial risk and Nasdaq compliance challenges.QUCY
Registration Filing29 Nov 2025